CPT code verified for 3D prostate tumor modeling software

A Current Procedural Terminology (CPT) code has been verified for ProstatID–—an artificial intelligence software for 3D prostate tumor modeling of suspected lesions detected on MRI—to facilitate reimbursement of use of the device by Medicare and United Healthcare, Bot Image announced in a news release.¹

The FDA granted 510(k) clearance to ProstatID in June 2022.

The CPT code 76377 may be used for ProstatID when the software is used in conjunction with a suitable CT, MRI, (CPT 72195, 72197 – pelvis MRI wo, w&wo contrast), or a transrectal ultrasound (CPT 76872).

"ProstatID allows radiologists a three-dimensional view of the relevant findings synthesized from the hundreds of images obtained during multiparametric prostate MRI. This map not only improves diagnosis but also guides the proceduralist during biopsies to target suitable areas and minimize overdiagnosis of clinically insignificant lesions,” says Eric M. Walser, MD, in the news release.¹ Walser is the John Sealy Distinguished Chairman and a professor of radiology at the University of Texas Medical Branch in Galveston, Texas.

ProstatID was trained using thousands of MRI image sets, radiological interpretations, guided biopsies, and pathology lab results. The software is designed to assign a probability of cancer to suspicious lesions and can also suggest a PI-RADS score. The outputs from the AI software also include a colorized heat map that indicates the location and extent of lesions on axial T2-weighted MRI images.

"These outputs were created by the inventors for the specific purposes of presenting an entire 3D view of the prostate with 3D lesions enclosed in order to provide physicians the 'big picture' of the patient's extent and aggressiveness of disease and also provide an excellent tool for cognitive targeting," said CEO of Bot Image, Randall Jones, DE, PhD, MBA, in the current news release.¹

The FDA granted 510(k) clearance to ProstatID in June 2022 for prostate lesion detection, segmentation, and classification.²

The device was also recently highlighted at the 2024 American Urological Association (AUA) Annual Meeting in San Antonio, Texas.According to a news release from Bot Image on the software introduction at the AUA meeting,³ ProstatID has a reported area under the receiver operating characteristic curve of 93.6%.

Urologist D. Russell Locke, MD, of Vantage Urologic Institute concluded in the release, "In my practice, I have seamlessly integrated ProstatID's 3D outputs into cognitive biopsies, surpassing the limitations of traditional fusion systems. The precision and clarity provided by ProstatID's axial and coronal views have significantly enhanced biopsy procedures, ensuring precise alignment and optimal treatment guidance."¹

References

1. Bot Image, Inc. announces verification of CPT payment code for its 3D reconstruction of prostate tumors detected using bpMRI. News release. Bot Image, Inc. Published online and accessed July 31, 2024. https://www.prnewswire.com/news-releases/bot-image-inc-announces-verification-of-cpt-payment-code-for-its-3d-reconstruction-of-prostate-tumors-detected-using-bpmri-302210026.html

2. Omaha-based MRI medical device company, Bot Image, receives FDA clearance for artificial intelligence software used in detection and diagnosis of prostate cancer. News release. Bot Image, Inc. August 4, 2022. Accessed July 31, 2024. https://botimageai.com/omaha-based-mri-medical-device-company-bot-image-receives-fda-clearance-for-ai/

3. Bot Image, Inc. introduced its prostate cancer detection, diagnosis, and screening software at urologist meeting in San Antonio, Texas. News release. Bot Image, Inc. May 16, 2024. Accessed July 31, 2024. https://www.prnewswire.com/news-releases/bot-image-inc-introduced-its-prostate-cancer-detection-diagnosis-and-screening-software-at-urologist-meeting-in-san-antonio-texas-302146778.html